NASDAQ:IMRN Immuron Q2 2026 Earnings Report $1.19 -0.05 (-4.03%) Closing price 09/16/2026 04:00 PM EasternExtended Trading$1.16 -0.02 (-2.10%) As of 04:31 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Immuron EPS ResultsActual EPS-$0.10Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AImmuron Revenue ResultsActual Revenue$1.40 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AImmuron Announcement DetailsQuarterQ2 2026Date2/25/2026TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Immuron Earnings HeadlinesImmuron Ltd ADR IMRNSeptember 9, 2026 | morningstar.comM3 Penny Stocks to Watch Today, September 8September 8, 2026 | tipranks.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result. | Porter & Company (Ad)Immuron Signs Exclusive US Distribution Deal for Digestive-Health Product PROIBSSeptember 4, 2026 | finance.yahoo.comImmuron Stock Surges 56% On U.S. Distribution Deal For PROIBSSeptember 4, 2026 | rttnews.comIMRN stock skyrockets 60%, heads for best day in over 2 years – what’s driving the super rally today?September 4, 2026 | msn.comSee More Immuron Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Immuron? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immuron and other key companies, straight to your email. Email Address About ImmuronImmuron (NASDAQ:IMRN) Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease, as well as used in antiviral activity against the COVID-19 virus in laboratory studies; and IMM-529, a clinical stage product for clostridium difficile infections. Immuron Limited was founded in 1994 and is based in Carlton, Australia.View Immuron ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Holiday Shopping Is Almost Here—And Target May Be Ready to Win Big3 Luxury Consumer Brands to Watch in a Beaten-Down SectorJackson’s Record Quarter Powers the Bull CaseMarex Stock Doubles on Record Profits, But Can the Rally Continue?The Ultimate Cyber Shield: CrowdStrike Rises Past $2352 "Cheap for a Reason" Airline Stocks That May Be Worth the RiskMarketBeat's Most Downgraded Stocks in Q3: 2 Look Cheap, 1 Looks Risky Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
